AH Europe 2021 | Kisaco Research

Shaping the Future of Animal Health

Watch the Highlights
Virtual Event
22-23 February, 2021

Why Attend?

Animal Health Innovation Europe is the sector’s premier investment forum in Europe showcasing the most exciting innovators in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.

To complement our investment pitches, we include keynote presentations and host CEO-level panel discussions that address the trends and market dynamics of the animal health industry, across all species.

Our virtual format gives us a unique opportunity with our programming in 2021 to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians and farmers today.  

Book now to come and see for yourself!

Innovation Showcase

Applications are now open for the Innovation Showcase at Animal Health Innovation Europe 2021. 

We are looking for examples of outstanding innovation in tech, nutrition, diagnostics, pharmaceuticals and biologicals for animal health and any solutions involved in the prediction, prevention, detection or treatment of disease. 

We will present these innovations in two categories – Companion Animal and Production Animal with 10 start-ups in each category.

Showcase applicants are eligible for a discounted ticket to come and meet the investors online.

CLICK HERE TO APPLY NOW

 

500+
Attendees
1500+
1-to-1 Meetings
200+
Start-ups
20
Emerging Companies Presenting
25+
Private Meetings per person

Speakers

 

Tina Hunt

General Manager UK & Ireland
Elanco Animal Health

Tina Hunt

General Manager UK & Ireland
Elanco Animal Health

Tina Hunt

General Manager UK & Ireland
Elanco Animal Health
 

Christine Middlemiss

UK Chief Veterinary Officer at Department for Environment
Food and Rural Affairs

Christine Middlemiss

UK Chief Veterinary Officer at Department for Environment
Food and Rural Affairs

Christine Middlemiss

UK Chief Veterinary Officer at Department for Environment
Food and Rural Affairs
 

Jeff Simmons

CEO
Elanco

Jeff Simmons

CEO
Elanco

Jeff Simmons

CEO
Elanco
 

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim
 

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division.

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

 

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy
 

Jamie Crittall

Co-founder
Virtual Recall Ltd.

Jamie qualified from Bristol Vet School in 1993.  He owns two separate UK veterinary practices – one, a family-owned 146-year old multi-branch practice and the other, a 7-year old start-up (which he has subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.

Jamie Crittall

Co-founder
Virtual Recall Ltd.

Jamie Crittall

Co-founder
Virtual Recall Ltd.

Jamie qualified from Bristol Vet School in 1993.  He owns two separate UK veterinary practices – one, a family-owned 146-year old multi-branch practice and the other, a 7-year old start-up (which he has subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.

Co-Founded with fellow veterinarian, Charlie Barton, as a result of their vision to enhance the intimate bond between all owners & their animals.  They help vets create more valued customer experiences and drive improved business performance, to deliver better health and financial outcomes. They currently have their patent-pending, communication solution, iRecall® installed in over 1300 practices worldwide.  It enables practices to send their clients their own bespoke messages, completely automatically, ensuring every animal and every client receive the appropriate communication - including immediate feedback - every time.

iRecall® has sent over 15 million automated and personalized messages by SMS, email & post this year to over 2.5 million clients.  helping them to become better informed and more engaged in the health and well-being of their 4.5 million animals, driven by their vets’ recommendations.  Improving compliance, adherence and greater practice loyalty, delivering a virtuous value circle. 

iRecall® also enhances practices’ digital reputations by capturing over 370 000 Net Promoter Scores, with an average score of over 80, with promoters encouraged to provide written testimonials and online reviews.

Jamie also has an all-encompassing knowledge and love for the media, being vet on set for film, tv & commercials for twenty plus years and a 5-year sabbatical in British television.  He appeared regularly as a vet on The Big Breakfast; Sky News; BBC1’s The Really Useful Show, and latterly, co-presenting Pet Rescue’s spin off series, Pet Rescuers and Pet Rescue Roadshow.  He has radio broadcast countrywide and is a regular speaker at UK veterinary business, technology and marketing seminars, conferences and events.  Jamie is a Trustee of the Petplan Charitable Trust. Married with three children and a menagerie of pets and he can often be found mountain biking around the Surrey Hills.

 

Robert Dawson

Co-Founder
Vet-AI

Robert Dawson

Co-Founder
Vet-AI

Robert Dawson

Co-Founder
Vet-AI
 

Davide Rossi

CEO
Fitbark

 

Davide Rossi

CEO
Fitbark

Davide Rossi

CEO
Fitbark

 

Davide Rossi is a Co-Founder and CEO of FitBark, a data-driven pet technology company focused on getting pets and their owners safe and healthy together. FitBark builds collar sensors and software infrastructure that helps humans in 140+ countries to develop real-time, comparative knowledge of their pet’s location, activity, quality of sleep, calorie balance, anxiety, skin conditions and overall health and behavior. FitBark is also a research-grade platform adopted by 100+ vet schools and research institutions to conduct research on new drugs, products and treatments related to mobility, anxious behaviors and skin conditions.

In a previous life, Davide designed Ferrari engines, co-founded BRM Model Cars, and managed Oil & Gas projects in Asia and the Middle East. More recently, he served as an investment banker with Deutsche Bank in New York, where he advised FinTech clients on capital raises and matters related to mergers and acquisitions.

Davide holds a M.S. in Mechanical Engineering from Università degli Studi di Padova (Italy) and a Master in Business Administration from the Massachusetts Institute of Technology.

 

Dr. Jude Capper

Sustainability Consultant

Dr. Jude Capper

Sustainability Consultant

Dr. Jude Capper

Sustainability Consultant
 

Aidan Connelly

Chief Executive Officer at Cainthus, President
AgriTech Capital

Aidan Connelly

Chief Executive Officer at Cainthus, President
AgriTech Capital

Aidan Connelly

Chief Executive Officer at Cainthus, President
AgriTech Capital
 

Tim Pfister

CEO
LiVET

Tim Pfister

CEO
LiVET

Tim Pfister

CEO
LiVET
 

Sandhya Sriram

CEO & Founder
Shiok Meats

Sandhya Sriram

CEO & Founder
Shiok Meats

Sandhya Sriram

CEO & Founder
Shiok Meats
 

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs
 

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

 

Kamran Adle

Partner
Octopus Ventures

Kamran Adle

Partner
Octopus Ventures

Kamran Adle

Partner
Octopus Ventures
 

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins Universi

 

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.

Dirk Ehle is married with three children.

 

Phil Wilkinson

Executive Director
2 Sisters Food Group

Phil Wilkinson

Executive Director
2 Sisters Food Group

Phil Wilkinson

Executive Director
2 Sisters Food Group
 

Lyndsay Chapman

CEO
CIEL

Lyndsay Chapman

CEO
CIEL

Lyndsay Chapman

CEO
CIEL
 

Amanda Burkardt

Founder and CEO
Nutripeutics

Amanda Burkardt

Founder and CEO
Nutripeutics

Amanda Burkardt

Founder and CEO
Nutripeutics
 

Matt Dobbs

Practice Leader Digital Technology
Stonehaven Consulting AG

Matt Dobbs

Practice Leader Digital Technology
Stonehaven Consulting AG

Matt Dobbs

Practice Leader Digital Technology
Stonehaven Consulting AG
 

Gudrun Ravetz

Senior Vice President
British Veterinary Association

Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.

Gudrun Ravetz

Senior Vice President
British Veterinary Association

Gudrun Ravetz

Senior Vice President
British Veterinary Association

Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.

 

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

For three years, Simon was the Animal Sciences & Aquaculture specialist for the Department for International Trade. Last year, he was appointed a GlobalScot in the animal health & aquaculture sector by the Office of the First Minister in Scotland.

Simon is a past president of the North of Ireland Veterinary Association and of the Northern Ireland Branch of BVA. He currently chairs the UK One Health Coordination Group and is one of two BVA representatives at the Federation of Veterinarians in Europe (FVE). He also chairs the FVE FishMedPlus Coalition.

A STEM Ambassador, he is also actively involved in the provision of veterinary careers advice, regularly mentoring applicants to veterinary school. He is also an ambassador for the livestock development charity, Send a Cow, and a trustee of the Animal Welfare Foundation.

Follow Simon on Twitter:
@simondocvet   @britishvets
#OneVeterinaryCommunity   #AStrongVoiceForVets

 

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd
 

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners
 

Joost Matthijssen

Director of Venturing
Nutreco

Joost Matthijssen

Director of Venturing
Nutreco

Joost Matthijssen

Director of Venturing
Nutreco
 

Patricia Barclay

International Life Science lawyer + Business Mentor
Bonaccord Law

Patricia Barclay

International Life Science lawyer + Business Mentor
Bonaccord Law

Patricia Barclay

International Life Science lawyer + Business Mentor
Bonaccord Law
 

Jason Clay

Senior Vice President
World Wildlife Fund

Jason Clay

Senior Vice President
World Wildlife Fund

Jason Clay

Senior Vice President
World Wildlife Fund
 

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

 

Kevin Cook

CEO
Sterling Pharma

Kevin Cook

CEO
Sterling Pharma

Kevin Cook

CEO
Sterling Pharma
 

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines.

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

 

Daniella Dos Santos

President
British Veterinary Association

Daniella Dos Santos

President
British Veterinary Association

Daniella Dos Santos

President
British Veterinary Association
 

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

Jo Malone

Chief Executive Officer
Vet Partners

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

In 2015 she became Managing Director of VetPartners and then CEO in 2016.

 

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.
 

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd
 

Gilles Guillemette

Vice President, Healthcare Services
Chewy

Gilles Guillemette

Vice President, Healthcare Services
Chewy

Gilles Guillemette

Vice President, Healthcare Services
Chewy
 

Caroline Povey

Policy Team Leader, Farming Productivity
Defra

Caroline Povey

Policy Team Leader, Farming Productivity
Defra

Caroline Povey

Policy Team Leader, Farming Productivity
Defra
 

Charlie Sheppy

AVP, Global Commercial Lead
MSD Animal Health Intelligence

Charlie Sheppy

AVP, Global Commercial Lead
MSD Animal Health Intelligence

Charlie Sheppy

AVP, Global Commercial Lead
MSD Animal Health Intelligence
 

Sophie Throup

Head of Agriculture, Fisheries and Sustainable Sourcing
WM Morrison Supermarkets Plc

Sophie Throup

Head of Agriculture, Fisheries and Sustainable Sourcing
WM Morrison Supermarkets Plc

Sophie Throup

Head of Agriculture, Fisheries and Sustainable Sourcing
WM Morrison Supermarkets Plc
 

Tom Zerzan

President, Companion Animal
Phibro

Tom Zerzan

President, Companion Animal
Phibro

Tom Zerzan

President, Companion Animal
Phibro

Photo Gallery

Photos from February 2020 now available to download and share - view the full photo gallery here

Advisory Board

Author:

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Author:

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Author:

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

Author:

Jean-Luc Michel

Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

George Gunn

Founder and Partner
Stonehaven Consulting AG

Author:

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Selection Committee

Author:

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Author:

Matthias Hofer

Managing Partner
Stonehaven Consulting Group

Matthias Hofer is a business leader with broad international experience and strength in sales, strategy and execution. He served on the executive committees of 2 major Animal Health companies for a total of 7 years.

Matthias lives in Switzerland with his wife and his two children. After completing his Master‘s degree at the University of St.Gallen (HSG), he started working for Novartis Animal Health (NAH) in Sydney, Australia in a project support role, serving the APAC region.
In 2006, Matthias was promoted first to Strategic Planning Manager for NAH and from there to Head of Strategy for the Animal Health Division. Between 2009 – 2013 Matthias led NAH’s Aqua Health business globally. This business today is amongst the top few companies in the Aqua-health industry.

During 2014 and with Elanco’s intention to buy NAH, Matthias served as integration leader for NAH on the Novartis side. In that role Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Once Elanco and NAH successfully merged, Matthias took on the role as Global Leader Emerging Business within Elanco. In that function Matthias was responsible for a total of five fast growing business areas, including Aqua, Vaccines, Enzymes and others.
Most recently Matthias has joined Stonehaven Consulting Group as a partner.
Stonehaven

Author:

Julia Stephanus

Founder and President
Avviare

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Author:

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management. 

Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture. 

Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.

Author:

Cindy Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Author:

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Author:

Paul Dick

President
Paul Dick & Associates Ltd and Managing Partner, Vet Venture Capital Inc.

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Author:

Sarai Kemp

VP Business Development
Trendlines AgTech

As VP Business Development for Trendlines Agtech since 2012, Sarai Kemp is responsible for directing the business and financial development and fund-raising strategies and activities for early-stage portfolio companies developing innovative technologies and products in aquaculture, food production, biopesticides and agrochemicals, and other related sectors. Trendlines Agtech is part of The Trendlines Group (www.trendlines.com). Trendlines invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies, and is involved in all aspects of its portfolio companies from technology development to business building.

Sarai brings more than 12 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.

Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.

Author:

Tom Prins

Head of Dealflow
Aqua-Spark

Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.    

Author:

Bruce Taillon

Senior Director, External Innovation
Elanco

Agenda

Download the 2021 agenda 

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Download the 2021 agenda

Partners

Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.

Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.

Headline Partner

Platinum Digital Innovation Partners

Knowledge Partner

Consulting Partner

Start-Up Development Partner

Gold Digital Innovation Partners

Media Partners

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Press Partnerships

Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:

  • Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
  • Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
  • Provide one free press pass to attend
  • Distribute promotional materials at the conference

If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:

Sarah Rowlands
Senior Marketing Manager
T: +44 (0)203 696 2920
E: sarah.rowlands@kisacoresearch.com

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Wednesday, November 4, 2020 to Friday, December 11, 2020
Tier 1
£399 + VAT
Super Early Bird Rate until 11th December- Save £200
Pre-revenue companies
Academics
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Wednesday, November 4, 2020 to Friday, December 11, 2020
Tier 2
£1,399 + VAT
Super Early Bird Rate until 11th December- Save £400
Animal Health Companies
Pharmaceutical Companies
Private Equity Investors & Brokers
Consultants, M&A Advisors
Vet Service Companies
Start-Up Incubators & Accelerators
CROs & CMOs
To increase your brand presence, contact Stephen: [email protected]com
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.